Speakers
-
Dr. Jean-Claude Cutz -
Dr. Rosalyn Jeurgens
Review biomarker testing of KRAS mutation subtypes Discuss KRAS mutation subtypes testing in clinical practice. Discuss the evolution of targeted therapies for KRAS mutation. Evaluate the clinical evidence of novel KRAS G12C inhibitors.
At the end of the sessions, participants will be able to:
- Demonstrate familiarity in the emerging role of KRAS as a therapeutic target in cancer
- Describe the options for biomarker testing for KRAS mutation subtypes
Co-developed with Amgen
